Axsome Therapeutics, Inc (AXSM) CEO Herriot Tabuteau on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/08/19
Here's Why Axsome Therapeutics Stock Rocketed 813% in the First Half of 2019The Motley Fool • 07/07/19
Axsome Shares Rally After FDA OKs Expedited Regulatory Filings For Depression DrugBenzinga • 05/06/19
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab FlopThe Motley Fool • 03/30/19
Axsome Adds To Strong Gains After FDA Grants Breakthrough Designation For Depression DrugBenzinga • 03/27/19
Axsome Therapeutics shares soar after FDA grants breakthrough designation to depression drugMarket Watch • 03/27/19